ProCE Banner Activity

Double Antibody–Drug Conjugate (DAD): Phase I Trial of Sacituzumab Govitecan + Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Conference Coverage

DAD, the first trial showing that ADCs can be given safely in combination, established the recommended phase II dose of SG plus EV in patients with treatment-resistant mUC, as well as demonstrating robust antitumor activity with the combination (ORR 70%).

Released: October 26, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc